CSR&D Research Career Development Transition Award Application

企业社会责任

• 批准号: 10663063
• 负责人: Josh Woolley
• 金额: --
• 依托单位: VETERANS AFFAIRS MED CTR SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10663063
• 关键词: Acceleration; Acute; Adherence; Affect; Agonist; Area; Award; Behavior; Behavioral; Behavioral Mechanisms; Caring; Cellular Phone; Chronic; Clinical; Clinical Trials; Cognitive; Consumption; Detection; Development; Diagnosis; Diagnostic; Disease; Doctor of Philosophy; Emotions; Epidemic; Eye; Face; Faculty; Feeling; Focus Groups; Funding; Goals; Health; Health Care Costs; Health system; Healthcare; Individual; Industry; Interdisciplinary Study; International; Intervention; K-Series Research Career Programs; Laboratories; Lead; Loneliness; Measures; Medical; Medical Students; Mental Health; Mental disorders; Mentors; Mission; Modification; Morbidity - disease rate; Motivation; Neuropeptides; Occupational; Outcome; Oxytocin; Pathologic; Pathway interactions; Patients; Performance; Personal Satisfaction; Persons; Pharmaceutical Preparations; Pharmacological Treatment; Phase; Physiological; Positioning Attribute; Post-Traumatic Stress Disorders; Postdoctoral Fellow; Prevalence; Privatization; Productivity; Psilocybin; Psyche structure; Psychiatric therapeutic procedure; Psychophysiology; Psychoses; Psychotherapy; Quality of life; Reporting; Research; Research Assistant; Research Personnel; Schizophrenia; Scientist; Services; Severities; Short-Term Memory; Site; Social Behavior; Social Functioning; Social Processes; Social isolation; Social support; Substance Use Disorder; Suicide; Talents; Testing; Time; Training; Transition Career Development Award (K22); United States National Institutes of Health; Veterans; Work; alcohol use disorder; attentional bias; clinical application; cognitive ability; cohesion; comorbidity; cost; craving; diagnostic strategy; disability; doctoral student; economic cost; ecstasy; effective therapy; efficacy trial; gaze; graduate student; improved; member; mortality; multidisciplinary; neural; neuroimaging; neuromechanism; neurophysiology; neuropsychiatric disorder; novel; opioid use disorder; pharmacologic; physical conditioning; pre-doctoral; program costs; programs; psychologic; psychosocial; randomized, clinical trials; receptor; reduce symptoms; service utilization; side effect; smartphone application; social; social cognition; social deficits; social situation; stimulant use disorder; treatment program; uptake; volunteer

There is an “epidemic of loneliness” with 20% of civilians and up to 50% of veterans reporting feeling lonely or socially isolated. This is clinically important because loneliness and social isolation are strong predictors of worse physical health and early mortality. Mental illness is intimately entwined with this epidemic because it both causes and is worsened by loneliness and social isolation. It is the social deficits of mental illness that most strongly contribute to loneliness and social isolation. These social deficits include difficulty understanding other people’s behavior and difficulty behaving appropriately in social situations. Despite their importance, these social deficits are poorly understood at the neural and behavioral levels and are difficult to quantify. Moreover, available treatments for them are inadequate. I am the Director of the Bonding and Attunement in Neuropsychiatric Disorders (BAND) lab, which comprises one junior faculty member supported by a CSR&D Career Development Award, 5 postdoctoral fellows including MDs and PhDs, 4 graduate students, 6 paid research assistants, over 20 volunteers. We believe the key to mental health and well-being starts with strong relationships. Our mission is to develop novel pharmacological and cognitive interventions for mental illness that enable patients to strengthen their connections to other people and the world. Our work has primarily focused on understanding the psychological, behavioral, physiological, and neural effects of administration of the neuropeptide oxytocin across multiple psychiatric illnesses. For example, we have conducted numerous studies determining the acute effects of oxytocin administration in individuals with schizophrenia. One highlight of this work is that we found that a single administration of oxytocin to individuals with schizophrenia normalized neural activity during high-level social cognitive processing and that this normalization was associated with improved behavioral performance. This work led to a VA CSR&D Merit Award to conduct the largest randomized clinical trial of repeated administration of oxytocin in schizophrenia to date. We have also conducted studies investigating oxytocin as a potential treatment for individuals with alcohol, opioid, and stimulant use disorders, and co-occurring post-traumatic stress disorder (PTSD) and alcohol use disorder (a common and difficult-to-treat comorbidity). We also recently completed a large laboratory-based study in healthy individuals to determine whether acute oxytocin administration can accelerate the development of team cohesion. This work led us to hypothesize that pharmacological treatments that affect social processes could be paired with psychosocial treatments to possibly achieve synergistically positive outcomes. To investigate this possibility, we have conducted studies pairing administration of various drugs with social effects, including oxytocin, 3,4-methylenedioxy-methamphetamine (MDMA), and psilocybin, with various psychotherapy interventions including group-based psychotherapy. In the non-pharmacological arena, we have been investigating attention bias modification delivered through a smartphone app as a treatment for PTSD. Our studies incorporate multiple analytic approaches including objective measures of social behavior such as eye-gaze, facial expressivity, team cohesion and performance, quantification of social cognitive abilities, neuroimaging approaches, laboratory-based craving induction paradigms, and quantification of psychophysiological changes and interpersonal synchrony. In sum, I have developed a broad and highly productive trans-diagnostic program of research and assembled a large, energetic, and multidisciplinary research group focused on developing and testing novel treatments for the difficult to treat social deficits that cut across most psychiatric disorders. By improving social deficits across disorders, veterans will have better social functioning and decreased symptom severity and will be able to more effectively mobilize their social support networks and engage in other psychiatric treatment. This will lead to better health outcomes and decreased costs for the VA health system.

有20％的平民和多达50％的退伍军人报告感到孤独或 社会孤立。这在临床上很重要，因为孤独和社会隔离是 身体健康和早期死亡率较差。精神疾病与这种流行病紧密联系在一起，因为它 孤独和社会孤立使这两种原因都恶化了。正是精神疾病的社会缺陷 最有力地助长了孤独和社会孤立。这些社会缺陷包括艰难的理解 在社交情况下，别人的行为和艰难的行为。尽管它们的重要性 这些社会缺陷在神经和行为层面上对很难量化，很难量化。 此外，他们的可用治疗不足。我是纽带和调整的主任 神经精神疾病（Band）Lab，由CSR和D的一名初级教师组成 职业发展奖，5名博士后研究员，包括MDS和PHD，4名研究生，6个工资 研究助理，20多名志愿者。我们相信心理健康和福祉的关键始于 牢固的关系。我们的使命是开发新颖的药理学和认知干预措施 精神疾病使患者能够加强与他人和世界的联系。我们的 工作主要集中于理解心理，行为，生理和神经效应 在多种精神病患者中给予神经肽催产素。例如，我们有 进行了大量研究，以确定氧施用对患者的急性影响 精神分裂症。这项工作的一个亮点是，我们发现对个体的氧气给药 精神分裂症使高级社会认知处理过程中的神经活动标准化，这 归一化与改善行为表现有关。这项工作导致了VA CSR＆D的优点 奖励进行精神分裂症中反复施用氧气的最大随机临床试验 日期。我们还进行了研究，研究氧加毒素是针对患有患者的潜在治疗方法 酒精，OIOID和刺激性使用障碍以及创伤后应激障碍（PTSD）和 酒精使用障碍（一种常见且难以治疗的合并症）。我们最近还完成了一个大型 在健康个体中基于实验室的研究，以确定急性催产素的给药是否可以 加速团队凝聚力的发展。这项工作使我们假设药理学 影响社会过程的治疗可以与社会心理治疗配对 实现协同积极的结果。为了调查这种可能性，我们进行了研究配对 给予具有社会作用的各种药物，包括氧气，3,4-甲基二氧基 - 甲基苯丙胺 （MDMA）和心理治疗干预措施，包括基于小组的心理治疗。在 非药理学领域，我们一直在研究通过 智能手机应用程序作为PTSD的治疗方法。我们的研究结合了多种分析方法，包括 社会行为的客观度量，例如眼睛凝视，面部表情，团队凝聚力和表现， 量化社会认知能力，神经影像学方法，基于实验室的渴望 范式和心理生理变化和人际同步的量化。总而言之 开发了一项广泛而高产的跨性诊断计划，并组装了一个大型，大型的 充满活力和多学科研究小组致力于开发和测试新的治疗方法 难以治疗大多数精神疾病的社会缺陷。通过改善社会缺陷 疾病，退伍军人将具有更好的社交功能和症状严重程度的降低，并且能够 更有效地动员其社会支持网络并进行其他精神病治疗。这将带领 为了改善健康状况并扩大VA卫生系统的成本。

项目成果

Posttraumatic stress disorder symptoms associated with protective and risky behaviors for coronavirus disease 2019.

• DOI: 10.1037/hea0001157
• 发表时间: 2022-03
• 期刊: Health psychology : official journal of the Division of Health Psychology, American Psychological Association
• 作者: Nishimi K;Borsari B;Marx BP;Tripp P;Woodward E;Rosen RC;Cohen BE;Maven D;Jiha A;Woolley JD;Neylan TC;O'Donovan A
• 通讯作者: O'Donovan A

Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption.

• DOI: 10.1177/02698811221131997
• 发表时间: 2023-01
• 期刊: JOURNAL OF PSYCHOPHARMACOLOGY
• 影响因子: 4.1
• 作者: Morton, Emma;Sakai, Kimberly;Ashtari, Amir;Pleet, Mollie;Michalak, Erin E.;Woolley, Josh
• 通讯作者: Woolley, Josh

The effects of intranasal oxytocin on black participants' responses to outgroup acceptance and rejection.

• DOI: 10.3389/fpsyg.2022.916305
• 发表时间: 2022
• 期刊: FRONTIERS IN PSYCHOLOGY
• 影响因子: 3.8
• 作者: Park, Jiyoung;Woolley, Joshua;Mendes, Wendy Berry
• 通讯作者: Mendes, Wendy Berry

"A sense of the bigger picture:" A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use.

• DOI: 10.1371/journal.pone.0279073
• 发表时间: 2022
• 期刊: PLOS ONE
• 影响因子: 3.7
• 作者: DellaCrosse, Meghan;Pleet, Mollie;Morton, Emma;Ashtari, Amir;Sakai, Kimberly;Woolley, Josh;Michalak, Erin
• 通讯作者: Michalak, Erin